Mycosis fungoides (MF) is a T-cell lymphoma that clinically is characterized by chronic progression of skin lesions and pathologically is composed of cerebriform lymphocytes that tend to infiltrate the epidermis (epidermotropism). MF is the most common type of T-cell lymphoma involving the skin and accounts for more than 50 % of all cases of cutaneous T-cell lymphoma (CTCL). Many authors use the term CTCL as a synonym for MF, but here we use the term CTCL more broadly. Patients with MF are mostly adults, and often elderly. The male to female ratio is 2:1. MF arises in and primarily involves skin, and commonly affects multiple areas. Involvement of blood at low levels is common. Extracutaneous dissemination may occur in advanced stages, mainly to lymph nodes, liver, spleen, and lungs. Bone marrow involvement at a low level can occur but morphologically obvious bone marrow involvement is rare.
KeywordsLymphoma Triad Retinoid Alopecia
- 1.Ralfkiaer EC, Sander CA, Smoller BR, Willemze R. Mycosis fungoides. In: Swerdlow SH, Harris NL, Jaffe ES, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. p. 296–8.Google Scholar
- 2.Wang SA. Mycosis fungoides. In: Medeiros J, editor. Diagnostic pathology: lymph nodes and spleen with extranodal sites. 1st ed. Altona: Amirsys; 2011. p. 10-36–49.Google Scholar
- 4.Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713–22.PubMedCrossRefGoogle Scholar
- 5.Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29:2598–607.PubMedCrossRefGoogle Scholar
- 12.Ralfkiaer E, Willemze R, Whittaker SJ. Sézary syndrome. In: Swerdlow SH, Harris NL, Jaffe ES, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. p. 299.Google Scholar
- 13.Wang SA. Sézary syndrome. In: Medeiros J, editor. Diagnostic pathology: lymph nodes and spleen with extranodal sites. 1st ed. Altona: Amirsys; 2011. p. 10-50–9.Google Scholar